Andere Sprachen EyePoint Pharmaceuticals, Inc.

Aktien

A2QJRU

US30233G2093

EYPT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 30.04.2024			% 5 Tage	% 1. Jan.
17.6 ^USD	-0.17%		+0.17%	-23.84%

02.04.	EyePoint Pharmaceuticals, Inc. erweitert wissenschaftlichen Beirat	CI
07.03.	Sektor-Update: Aktien des Gesundheitswesens am Donnerstag vor der Glocke uneinheitlich	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	17.04.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	16.04.
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists	02.04.
EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	02.04.
EyePoint Pharmaceuticals : Investor Presentation March 2024	22.03.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	18.03.
EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index	18.03.
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	07.03.
EyePoint Pharmaceuticals' Q4 Net Loss Narrows, Revenue Advances; Shares Up Pre-Bell	07.03.
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q4 Revenue $14M	07.03.
EyePoint Pharmaceuticals: Q4 Earnings Snapshot	07.03.
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments	07.03.
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07.03.
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
North American Morning Briefing : Powell Still in -2-	07.03.
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	04.03.
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer	04.03.
EyePoint Pharmaceuticals, Inc. Announces Executive Changes	04.03.
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024	29.02.
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences	27.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen EyePoint Pharmaceuticals, Inc.

Aktien

A2QJRU

US30233G2093

EYPT

Andere Sprachen

Filter